Trogenix Secures $95M Series A to Advance "Trojan Horse" Gene Therapy for Glioblastoma
Key Insights
Edinburgh-based biotech Trogenix (search) raised $95 million in Series A funding led by IQ Capital (search) to advance its novel gene therapy platform targeting aggressive solid tumors (search).
The company's proprietary Odysseus platform uses "Trojan Horse" delivery with Synthetic Super Enhancers (search) to selectively target cancer (search) cells while preserving healthy tissue.
Preclinical studies in glioblastoma (search) models showed complete responses with no toxicity or relapse, prompting a Phase I trial expected to begin in early 2026.
Edinburgh-based biotech Trogenix (search), a University of Edinburgh spinout, has secured £70 million (~$95 million) in Series A funding to accelerate development of its revolutionary gene therapy platform targeting aggressive solid tumors (search). The financing round, led by IQ Capital (search) with participation from 4BIO Capital (search), Cancer Research Horizons (search), Eli Lilly, and other investors, will drive the company's pipeline into clinical trials, beginning with its lead program for glioblastoma (search).
The funding represents the largest investment to date from Cancer Research Horizons (search), whose CEO Iain Foulkes noted that the partnership "reflects their commitment to advancing science with the potential to transform cancer (search) treatment, particularly as we advance into clinical trials for glioblastoma (search), one of the hardest cancers to treat."
Revolutionary "Trojan Horse" Approach
Trogenix (search)'s proprietary Odysseus platform employs what CEO Ken Macnamara describes as a "Trojan Horse" precision delivery method that combines cancer (search) cell killing with immune stimulation. The approach uses proven AAV vectors (search) to deliver proprietary Synthetic Super Enhancers (search) (SSEs) directly to tumor cells without immune system detection.
"Like the mythological wooden horse that appeared as a gift but contained hidden warriors, our delivery system goes 'under the radar' and hides until the time is right to kill the cancer (search) cells from within," Macnamara explained. Once inside, the SSE acts as an intelligent switch that identifies cancerous cell states and activates therapeutic payloads accordingly, then switches off once cancer cells are eliminated to preserve healthy surrounding tissue.
The SSEs selectively identify the severity of cancerous cell states and can deploy both a cytotoxic prodrug converting enzyme and an immune stimulating cytokine together. This dual mechanism simultaneously eliminates tumor cells and reawakens the immune system to mount a stronger response, effectively revealing the cancer (search) to the body's natural defenses.
Promising Preclinical Results Drive Clinical Advancement
The company's confidence in advancing to human studies stems from exceptionally promising preclinical results. TGX-007 was designed and validated using one of the world's largest biobanks of primary patient cell lines and patient tissue for glioblastoma (search) multiforme (GBM). The therapy demonstrated exquisite targeting of patient tumor cells while leaving surrounding healthy tissue untouched, with activity and selectivity maintained across the full spectrum of patient disease heterogeneity.
In preclinical models that faithfully replicate human glioblastomas, TGX-007 demonstrated complete responses with no observed toxicity, no relapse, and reproducibility across many independent experiments—even at lower doses. Notably, the treatment triggered a lasting systemic immune response by combining cancer (search) cell killing with simultaneous immune system activation and education, suggesting curative potential.
Addressing Glioblastoma's Unique Challenges
Glioblastoma (search) presents particularly formidable treatment challenges, with only 25% of patients surviving beyond one year. According to Macnamara, brain cancers have been severely limited by their biological characteristics, including difficulties in harnessing immune system effectiveness due to the brain's specialized environment and blood-brain barrier. The tumors also infiltrate local healthy tissue, making complete surgical resection impossible.
"The complexity of glioblastoma (search) as an 'ecosystem of different species of cancer (search)' means that traditional approaches targeting single genetic mutations have also proven insufficient," Macnamara noted. The tumor's ability to corrupt the body's natural immune responses and its capacity for rapid adaptation through transcriptional plasticity have made it particularly resistant to conventional therapies.
Trogenix (search)'s approach addresses these challenges through what Macnamara describes as "unsurpassed spatial and temporal precision in targeting cancer (search) cells while preserving healthy tissue" using AAV vectors (search) with SSE switch technology and well-understood cytotoxic and immunotherapy payloads.
Clinical Trial Design and Timeline
The first Phase I study for TGX-007 in glioblastoma (search) is anticipated to commence in Q1 2026, aiming to recruit 15 patients to assess safety and select an appropriate dose for Phase II progression. The therapy will be administered three weeks before standard-of-care treatment, which comprises surgery, chemotherapy, and/or radiotherapy.
"This study design is key for an immunotherapy as it enables treatment when patients still have a functioning immune system, providing the best chance of preventing any tumor regrowth," Macnamara explained.
Paradigm Shift Toward Curative Potential
Trogenix (search) aims to fundamentally transform the current dismal prognosis for glioblastoma (search) patients through what Macnamara calls "one and done" potential—representing a paradigm shift from managing cancer (search) as a chronic disease to potentially curing it entirely.
"Our aim is to achieve breakthrough therapies that enable patients to gain years, or even decades, of additional quality life—and in the best cases, eradicate the tumor population entirely," he stated. The goal is to move cancers from fatal diseases into long-term manageable or curable conditions.
The company's mission extends beyond glioblastoma (search), with the Odysseus platform designed to create precision therapies for all aggressive, treatment-resistant solid tumors (search). Unlike conventional treatments requiring repeated dosing with significant side effects, Trogenix (search)'s approach potentially provides long-term protection against cancer (search) relapses while eliminating harmful side effects associated with traditional surgery, chemotherapy, and radiotherapy.